Scarica l'app Stockscreener
27.65
0.47%
-0.13
Dopo l'orario di chiusura:
27.67
0.02
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$27.78
Aprire:
$27.69
Volume 24 ore:
27.64M
Relative Volume:
0.67
Capitalizzazione di mercato:
$157.60B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
21.20
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-4.03%
1M Prestazione:
+2.22%
6M Prestazione:
+1.80%
1 anno Prestazione:
+12.54%
Intervallo 1D:
$27.40
$27.75
Intervallo di 1 settimana:
$27.40
$28.69
Portata 52W:
$23.58
$29.21
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.65 | 158.34B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,123.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.35 | 643.64B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
255.00 | 443.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.71 | 363.98B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Why Pfizer (NYSE:PFE) Is Standing Out As Defensive Healthcare Draws Notice - Kalkine Media
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot - Yahoo Finance
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? - Trefis
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - proactiveinvestors.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
NVAX: Sanofi and Pfizer deals fuel pipeline expansion, milestone payments, and global vaccine market growth - TradingView
Pfizer Stock: Firing On All Cylinders (NYSE:PFE) - Seeking Alpha
Pfizer Inc. stock steadies as analysts lift targets and 2026 guidance firms - ad-hoc-news.de
Novartis India zooms 51% in 3 days; what's driving the pharma stock? - Business Standard
Pfizer stock heads into the open after a 2.3% slide - ad-hoc-news.de
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks - Yahoo Finance
Pfizer Inc. stock slips as BMO Capital keeps positive stance and options activity spikes - ad-hoc-news.de
Novartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3% - BusinessLine
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - Yahoo Finance
Novartis India to Acquire Pfizer’s BP Drug Brands for ₹1,250 Crore - Chemical Industry Digest
Mandi Rollerson Takes on New AI Change and Adoption Leadership Role at Pfizer - hrtoday.in
Why Pfizer Stock Was so Healthy in August - Yahoo Finance
Inside Pfizer’s Fight Against Counterfeit Medicine - Pfizer
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
PFE Stock Quote Price and Forecast - CNN
Why Is Pfizer (NYSE:PFE) Trading At Such A Wide Discount To Its Healthcare Peers? - Kalkine Media
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceSeptember 8, 2026 - BioSpace
💊 Pfizer to discontinue Minipress XL in India 🤝 Novartis India buys the brand for ₹1,250 crore 📉 But Pfizer India gets just ₹131 crore of the deal Ekta Batra #Pfizer #Novartis #MinipressXL #PfizerIndia #NovartisIndia #CNBCTV18Digital - LinkedIn
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Novartis India acquires Pfizer brands for $132m - Yahoo Finance
Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13% - Business Today
Novartis India to Acquire Minipress, Minipres Trademarks From Pfizer for Rs 1,250 Crore - Medical Dialogues
Pfizer to Discontinue Minipress XL in India, Receives USD 13.9 Mn From US Parent - Medical Dialogues
Pfizer stock heads into the open after a flat close - ad-hoc-news.de
Pfizer (PFE) Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - Yahoo Finance
Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore - Deccan Chronicle
This Is What I'd Do With Pfizer Stock Right Now - The Globe and Mail
Novartis India to Acquire Pfizer’s Minipress Trademarks for Rs 1,250 Crore - ChemAnalyst
Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore - BusinessLine
ChrysCap-controlled Novartis India to buy Pfizer’s blood pressure brand Minipress - VCCircle
Novartis India buys Minipress brands from Pfizer for ₹1,250 crore - Business Standard
Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore - ET Manufacturing
Novartis India to Buy Pfizer’s Minipress Brand for Rs 1,250 Cr - Equitypandit
Pfizer Inc. stock gains on Minipress XL exit and solid Q2 2026 figures - ad-hoc-news.de
Novartis India to acquire Minipress, Minipres Trademarks from Pfizer for Rs 1,250 crore - Business Upturn
Novartis India: Why Is the Pharma Stock Spending ₹1,250 Crore to Acquire Pfizer’s Minipress Brand? - Trade Brains
Pfizer, Inc. (PFE) Stock Analysis: Evaluating the 6.05% Dividend Yield and Its Implications for Investors - DirectorsTalk Interviews
Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks - latestly.com
Pfizer to Receive Rs 131.38 Crore After Minipress XL Discontinuation; Know Details - Dalal Street Investment Journal
Novartis India to acquire Pfizer trademarks 'Minipress' and 'Minipres' for Rs 1,250 crore - Mid-Day
Novartis India buys Minipress, Minipres rights from Pfizer for ₹1,250cr - NewsBytes
Novartis India Buys Minipress From Pfizer For ₹1,250 Crore - Whalesbook
Minipress changes hands: Novartis India buys Pfizer brands for Rs 1,250 crore - Moneycontrol.com
Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore - The Economic Times
Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore - BusinessLine
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.58%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):